At a glance
ClinicalIndex Comparison RecordN/ACompleted· 200 enrolled
Drug / intervention
Zilver® PTX® Drug-Eluting Peripheral Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Zilver® PTX® Drug-Eluting Peripheral Stent Post-Approval Study
In Brief
A clinical study evaluating Zilver® PTX® Drug-Eluting Peripheral Stent for Peripheral Arterial Disease. Completed, enrolled 200 participants across 17 sites.
Detailed Summary
The Zilver® PTX® V Clinical Study is a post-market clinical trial required by the US FDA to provide continued evaluation of the safety and effectiveness of the Zilver PTX Drug-Eluting Peripheral Stent in treatment of narrowing of the femoropopliteal arteries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Disease
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 2013
Enrollment StartAug 2013
Primary CompletionNov 2016
Study CompletionFeb 2021
TodayJul 2026
First PostedJul 17, 2013
Enrollment StartAug 1, 2013
Primary CompletionNov 18, 2016
Study CompletionFeb 15, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 13.0 years ago
Interventions
Zilver® PTX® Drug-Eluting Peripheral Stentdevice
Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.